Compare Johnson & Johnson (JNJ) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs NextEra Energy, Inc. — how do they compare? Johnson & Johnson trades at $250.19 (market cap $598.96B), while NextEra Energy, Inc. trades at $87.96 (market cap $183.53B). The key difference: Johnson & Johnson is far larger — about 3.3× NextEra Energy, Inc.'s market cap, and NextEra Energy, Inc. pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| JNJ | NEE | |
|---|---|---|
Market Cap | $598.96B | $183.53B |
Volume | 6,156,228 | — |
Sector | Health | Utilities |
52-Week High | $267.24 | $97.88 |
52-Week Low | $164.36 | $69.77 |
Enterprise Value | $631.90B | $285.94B |
Dividend Yield | 2.15% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
NextEra Energy (NEE) trades at $87.82, down 1.1% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed Q1 2026 earnings, beating estimates with $1.09 EPS versus $1.03 expected, but missed Q4 2025. Revenue for 2025 reached $27.41B with a net income margin of 29.37%. Recent news highlights a planned $59B annual capex through 2032 and a merger filing with Dominion Energy to expand market reach.
Outlook remains positive with analyst consensus price target of $101.88 (16% upside), supported by 66.7% buy ratings. Key risks include high capital expenditures straining cash flow and regulatory hurdles for the Dominion merger. The stock offers growth potential from clean energy investments but faces execution and debt concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
